

Karina Dahl Steffensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6806005/publications.pdf>

Version: 2024-02-01

99
papers

3,627
citations

186254

28
h-index

144002

57
g-index

100
all docs

100
docs citations

100
times ranked

5324
citing authors

#	ARTICLE	IF	CITATIONS
1	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2403-2415.	27.0	627
2	Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. <i>Cell Cycle</i> , 2009, 8, 158-166.	2.6	460
3	Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. <i>Lancet Oncology</i> , The, 2018, 19, 337-346.	10.7	235
4	Gynecologic Cancers in Pregnancy: Guidelines of a Second International Consensus Meeting. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 394-403.	2.5	198
5	Cancers take their Toll—the function and regulation of Toll-like receptors in cancer cells. <i>Oncogene</i> , 2008, 27, 225-233.	5.9	192
6	The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 117, 109-116.	1.4	100
7	What Works in Implementing Patient Decision Aids in Routine Clinical Settings? A Rapid Realist Review and Update from the International Patient Decision Aid Standards Collaboration. <i>Medical Decision Making</i> , 2021, 41, 907-937.	2.4	77
8	Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian Cancer. <i>Journal of Oncology</i> , 2011, 2011, 1-12.	1.3	74
9	Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGE). <i>Cancer Medicine</i> , 2021, 10, 208-219.	2.8	69
10	The Relationship of Platinum Resistance and ERCC1 Protein Expression in Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 820-825.	2.5	68
11	Lessons in Integrating Shared Decision-Making Into Cancer Care. <i>Journal of Oncology Practice</i> , 2018, 14, 229-235.	2.5	66
12	Systematic Development of Patient Decision Aids: An Update from the IPDAS Collaboration. <i>Medical Decision Making</i> , 2021, 41, 736-754.	2.4	59
13	The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. <i>Gynecologic Oncology</i> , 2010, 118, 167-171.	1.4	53
14	Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab. <i>European Journal of Cancer</i> , 2014, 50, 2611-2618.	2.8	50
15	Delta tocotrienol in recurrent ovarian cancer. A phase II trial. <i>Pharmacological Research</i> , 2019, 141, 392-396.	7.1	47
16	Prognostic Impact of Prechemotherapy Serum Levels of HER2, CA125, and HE4 in Ovarian Cancer Patients. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1040-1047.	2.5	44
17	Supraclavicular recurrence after early breast cancer: a curable condition?. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 815-822.	2.5	37
18	Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1549.	2.8	37

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 257-265.	2.5	35
20	Characteristics of patients with cervical cancer during pregnancy: a multicenter matched cohort study. An initiative from the International Network on Cancer, Infertility and Pregnancy. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 676-682.	2.5	35
21	The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: Data from CALYPSO trial (a GINECO-GCIG study). <i>Gynecologic Oncology</i> , 2013, 130, 289-294.	1.4	34
22	Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1842-1849.	2.5	33
23	Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 551-557.	2.5	33
24	Estimation of Immunohistochemical Expression of VEGF in Ductal Carcinomas of the Breast. <i>Journal of Histochemistry and Cytochemistry</i> , 2011, 59, 750-760.	2.5	32
25	Improved Classification of Epithelial Ovarian Cancer: Results of 3 Danish Cohorts. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1592-1600.	2.5	32
26	Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer. <i>European Journal of Cancer</i> , 2020, 125, 121-129.	2.8	32
27	Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab. <i>Journal of Ovarian Research</i> , 2012, 5, 23.	3.0	29
28	Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 995-1003.	2.5	28
29	The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 180-189.	1.4	28
30	Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma. <i>Acta Oncologica</i> , 2020, 59, 652-659.	1.8	28
31	Providing Balanced Information about Options in Patient Decision Aids: An Update from the International Patient Decision Aid Standards. <i>Medical Decision Making</i> , 2021, 41, 780-800.	2.4	28
32	Prognostic Importance of Vascular Endothelial Growth Factor-A Expression and Vascular Endothelial Growth Factor Polymorphisms in Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 578-584.	2.5	27
33	Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 547-553.	4.7	27
34	Mutant Epidermal Growth Factor Receptor in Benign, Borderline, and Malignant Ovarian Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 3278-3282.	7.0	26
35	Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression. <i>International Journal of Oncology</i> , 2014, 44, 1736-1744.	3.3	25
36	The Prognostic and Predictive Value of Combined HE4 and CA-125 in Ovarian Cancer Patients. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1474-1482.	2.5	23

#	ARTICLE	IF	CITATIONS
37	Implementing shared decision making in Denmark: First steps and future focus areas. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , 2017, 123-124, 36-40.	0.9	23
38	Factors Affecting Patient Decision-making on Surgery for Lumbar Disc Herniation. <i>Spine</i> , 2019, 44, 143-149.	2.0	23
39	Panitumumab and Pegylated Liposomal Doxorubicin in Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type: The PaLiDo Study, a Phase II Nonrandomized Multicenter Study. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 73-80.	2.5	21
40	A prospective cohort study of shared decision making in lung cancer diagnostics: Impact of using a patient decision aid. <i>Patient Education and Counseling</i> , 2019, 102, 1961-1968.	2.2	21
41	What matters in clinical trial decision-making: a systematic review of interviews exploring cancer patients' experiences. <i>Scandinavian Journal of Caring Sciences</i> , 2019, 33, 266-278.	2.1	21
42	Satisfaction with care and adherence to treatment when using patient reported outcomes to individualize follow-up care for women with early breast cancer – a pilot randomized controlled trial. <i>Acta Oncologica</i> , 2020, 59, 444-452.	1.8	21
43	Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival. <i>European Journal of Cancer</i> , 2021, 149, 128-133.	2.8	20
44	The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1390-1398.	2.5	19
45	Maternal and obstetrical outcome in 35 cases of well-differentiated thyroid carcinoma during pregnancy. <i>Laryngoscope</i> , 2018, 128, 1493-1500.	2.0	17
46	Proactive use of PROMs in ovarian cancer survivors: a systematic review. <i>Journal of Ovarian Research</i> , 2019, 12, 63.	3.0	17
47	The impact of shared decision making on time consumption and clinical decisions. A prospective cohort study. <i>Patient Education and Counseling</i> , 2021, 104, 1560-1567.	2.2	17
48	Gynecologic Oncology Training Systems in Europe. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1500-1506.	2.5	16
49	Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma. <i>Melanoma Research</i> , 2017, 27, 218-223.	1.2	16
50	How participatory action research changed our view of the challenges of shared decision-making training. <i>Patient Education and Counseling</i> , 2018, 101, 639-646.	2.2	16
51	Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status. <i>Cancer Treatment and Research Communications</i> , 2018, 14, 7-12.	1.7	16
52	The impact of a patient decision aid on shared decision-making behaviour in oncology care and pulmonary medicine – A field study based on real-life observations. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 1121-1130.	1.8	16
53	Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer. <i>Translational Oncology</i> , 2019, 12, 968-972.	3.7	15
54	<p>Are patient-reported outcomes useful in post-treatment follow-up care for women with early breast cancer? A scoping review</p>. <i>Patient Related Outcome Measures</i> , 2019, Volume 10, 117-127.	1.2	15

#	ARTICLE	IF	CITATIONS
55	Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. <i>Gynecologic Oncology</i> , 2022, 164, 245-253.	1.4	15
56	Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer. <i>Oncology Letters</i> , 2016, 11, 3967-3974.	1.8	13
57	Post-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counseling. <i>European Journal of Human Genetics</i> , 2016, 24, 1104-1111.	2.8	13
58	Shared decision making when patients consider surgery for lumbar herniated disc: development and test of a patient decision aid. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 190.	3.0	13
59	The promise of shared decision making in healthcare. <i>AMS Review</i> , 2019, 9, 105-109.	2.5	13
60	Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy. <i>Journal of Ovarian Research</i> , 2020, 13, 59.	3.0	13
61	Trust-Based Partnerships Are Essential " and Achievable " in Health Care Service. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1896-1906.	3.0	12
62	ePRO-based individual follow-up care for women treated for early breast cancer: impact on service use and workflows. <i>Journal of Cancer Survivorship</i> , 2021, 15, 485-496.	2.9	11
63	Immunohistochemical Expression of Platelet-Derived Growth Factor Receptors in Ovarian Cancer Patients with Long-Term Follow-Up. <i>Pathology Research International</i> , 2012, 2012, 1-8.	1.4	10
64	Predicting brain metastases of breast cancer based on serum S100B and serum HER2. <i>Oncology Letters</i> , 2013, 6, 1265-1270.	1.8	10
65	Practitioners'™ views on shared decision-making implementation: A qualitative study. <i>PLoS ONE</i> , 2021, 16, e0259844.	2.5	9
66	Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer. <i>BMC Cancer</i> , 2010, 10, 185.	2.6	7
67	Blood natural killer cells during treatment in recurrent ovarian cancer. <i>Acta OncolÃ³gica</i> , 2020, 59, 1365-1373.	1.8	7
68	The PROMova study comparing active and passive use of patient-reported outcome measures in ovarian cancer follow-up: effect on patient-perceived involvement, satisfaction with care, and usefulness. <i>Acta OncolÃ³gica</i> , 2021, 60, 434-443.	1.8	7
69	Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. <i>Gynecologic Oncology</i> , 2021, 162, 375-381.	1.4	7
70	Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement. <i>Clinica Chimica Acta</i> , 2021, 522, 152-157.	1.1	7
71	DNA-repair ERCC1 Gene Polymorphisms in Epithelial Ovarian Cancer and Relation to Platinum Resistance and Survival. <i>Journal of Cancer Therapy</i> , 2011, 02, 140-147.	0.4	7
72	Patients' experiences of the decision-making process for clinical trial participation. <i>Australian Journal of Cancer Nursing</i> , 2022, 24, 65-72.	1.6	7

#	ARTICLE	IF	CITATIONS
73	Shared decision making in high-grade glioma patientsâ€”a systematic review. <i>Neuro-Oncology Practice</i> , 2020, 7, 589-598.	1.6	6
74	Shared decision making with breast cancer patients: impact on patient engagement and fear of recurrence. Protocol for a Danish randomized trial in radiotherapy (DBCG RT SDM). <i>Acta OncolÃ³gica</i> , 2021, 60, 1032-1037.	1.8	6
75	Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer â€” an ancillary data analysis of the VELIA trial. <i>Gynecologic Oncology</i> , 2022, 164, 278-287.	1.4	6
76	Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer. <i>Cancers</i> , 2022, 14, 1766.	3.7	6
77	Implementation of patient-centred care in Denmark: The way forward with shared decision-making. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , 2022, 171, 36-41.	0.9	6
78	Quantitative detection of HER2 protein concentration in breast cancer tissue does not increase the number of patients eligible for adjuvant HER2-targeted therapy. <i>Oncology Reports</i> , 2013, 29, 1475-1482.	2.6	5
79	Development of a Patient Decision Aid to Support Shared Decision Making for Patients with Recurrent High-Grade Glioma. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7396.	2.6	5
80	Preoperative Serum Levels of Epidermal Growth Factor Receptor, HER2, and Vascular Endothelial Growth Factor in Malignant and Benign Ovarian Tumors. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2008, 1, 127-134.	0.2	4
81	HOXA9-methylated DNA as a diagnostic biomarker of ovarian malignancy. <i>Biomarkers in Medicine</i> , 2021, 15, 1309-1317.	1.4	4
82	The Long Non-Coding RNA SNHG12 as a Mediator of Carboplatin Resistance in Ovarian Cancer via Epigenetic Mechanisms. <i>Cancers</i> , 2022, 14, 1664.	3.7	4
83	The challenge of involving old patients with polypharmacy in their medication during hospitalization in a medical emergency department: An ethnographic study. <i>PLoS ONE</i> , 2021, 16, e0261525.	2.5	4
84	VEGF in the Development of Ovarian Malignancy. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2011, 4, 19-25.	0.2	3
85	The Prognostic Value of Syndecan-1 in Ovarian Cancer Patients with Long-Term Follow up. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2011, 4, 12-18.	0.2	3
86	Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer. <i>Anticancer Research</i> , 2020, 40, 5255-5261.	1.1	3
87	When life gives you no choice: Context of decisionâ€”making when offered an oncology clinical trial. <i>Scandinavian Journal of Caring Sciences</i> , 2021, , .	2.1	3
88	Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1444-1449.	2.5	3
89	Shared Decision Making with Acutely Hospitalized, Older Poly-Medicated Patients: A Mixed-Methods Study in an Emergency Department. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 6429.	2.6	3
90	A design-led patient campaign development process for disseminating the concept of shared decision making. <i>Design for Health</i> , 2019, 3, 305-323.	0.8	2

#	ARTICLE	IF	CITATIONS
91	Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 751-759.	2.3	2
92	Methylated circulating tumor DNA as a potential marker of PARP inhibitor efficiency in BRCA mutated ovarian cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5540-5540.	1.6	2
93	Experiences of involvement in decision-making for patients with breast cancer. A phenomenological-hermeneutical study. <i>European Journal for Person Centered Healthcare</i> , 2018, 6, 237.	0.3	2
94	Platelet-Derived Growth Factor Gene Polymorphisms in Patients With Ovarian Cancer. <i>Clinical Ovarian and Other Gynecologic Cancer</i> , 2012, 5, 10-16.	0.1	1
95	Proposing a Bill of Rights for Patients With Cancer. <i>JCO Oncology Practice</i> , 2020, 16, 121-123.	2.9	1
96	Treosulfan in platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, ijgc-2021-002395.	2.5	1
97	Association of patient-reported outcomes and ovarian cancer recurrence. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1248-1259.	2.5	1
98	Tissue immune response in epithelial ovarian carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2625-2625.	1.6	1
99	Decisional needs of patients with recurrent high-grade glioma and their families. <i>Neuro-Oncology Practice</i> , 0, , .	1.6	1